Vaccine strategies against Epstein-Barr virus-associated diseases: Lessons from studies on cytotoxic T-cell-mediated immune regulation

Immunological Reviews

Volumn 170, Issue , 1999, Pages 49-64

  Khanna, Rajiv ^a   Moss, Denis J ^a   Burrows, Scott R ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS VACCINE;

BURKITT LYMPHOMA; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HODGKIN DISEASE; IMMUNOREGULATION; INFECTIOUS MONONUCLEOSIS; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGENS, VIRAL; BURKITT LYMPHOMA; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; INFANT, NEWBORN; INFECTIOUS MONONUCLEOSIS; MICE; PHENOTYPE; PRIMATES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES;

EID: 0032885281     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01328.x     Document Type: Review

References (112)

1. 1. Epstein M, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964;1:702-703.
2. 2. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995;59:387-405.
3. 3. Moss DJ, Schmidt C, Elliott S, Suhrbier A, Burrows S, Khanna R. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv Cancer Res 1996;69:213-245.
4. 4. Rickinson AB, Kieff E. Epstein-Barr Virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott-Raven Publishers; 1996. p. 2397-2446.
5. 5. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997;15:
6. 6. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984;310:1225-1230.
7. 7. Sixbey JW, Shirley P, Chesney PJ. Buntin DM, Resnick L. Detection of a second widespread strain of Epstein-Barr virus. Lancet 1989;2:761-765.
8. 8. Rowe M, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987;6:2743-2751.
9. 9. Rymo L. Identification of transcribed regions of Epstein-Barr virus DNA in Burkitt lymphoma-derived cells. J Virol 1979;32:8-18.
10. 10. Howe JG, Shu MD. Epstein-Barr virus small RNA (EBER) genes: unique transcription units that combine RNA polymerase II and III promoter elements. Cell 1989;57:825-834.
11. 11. Wang F, Blaese RM, Zoon KC, Tosato G. Suppressor T-cell clones from patients with acute Epstein-Barr virus-induced infectious mononucleosis. J Clin Invest 1987;79:7-14.
12. 12. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993;90:9150-9154.
13. 13. Miller CL, Lee JH, Kieff E, Longnecker R. An integral membrane protein (lmp2) blocks reactivation of epstein-barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA 1994;91:772-776.
14. 14. Longnecker R, Miller CL, Tomkinson B, Miao XQ, Kieff E. Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol 1993;67:5068-5074.
15. 15. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 1989;340:393-397.
16. 16. Knecht H, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993;82:2937-2942.
17. 17. Epstein MA, Achong BG. Pathogenesis of infectious mononucleosis. Lancet 1977;2:1270-1273.
18. 18. Crawford DH, et al. Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft. Lancet 1980;1:1355-1356.
19. + cytotoxic T cell recognition of endogenously processed antigen. J Immunol 1990;144:2789-2794.
20. + T-cells as a sign of in vivo activation in infectious mononucleosis. Clin Exp Immunol 1991;83:447-451.
21. 21. Moss DJ, Rickinson AB, Pope JH. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 1978;22:662-668.
22. 22. Moss DJ, Rickinson AB, Pope JH. Long term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T-cells in virus-infected leukocyte cultures. Int J Cancer 1979;23:618-625.
23. 23. Moss DJ, Misko IS, Burrows SR, Burman K, McCarthy R, Sculley TB. Cytotoxic T-cell clones discriminate between A-and B-type Epstein-Barr virus transformants. Nature 1988;331:719-721.
24. 24. Burrows SR, Misko IS, Sculley TB, Schmidt C, Moss DJ. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A-and B-type transformants. J Virol 1990;64:3974-3976.
25. 25. Khanna R, et al. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992;176:169-176.
26. 26. Misko IS, Schmidt C, Moss DJ, Burrows SR, Sculley TB. Cytotoxic T lymphocyte discrimination between type A Epstein-Barr virus transformants is mapped to an immunodominant epitope in ebna 3. J Gen Virol 1991;72:405-409.
27. + EBV specific CTL.. J Immunol 1997;157:3619-3625.
28. 28. Khanna R, Burrows SR, Steigerwald-Mullen PM, Thomson SA, Kurilla MG, Moss DJ. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen I: implications for viral persistence and tumor surveillance. Virology 1995;214:633-637.
29. 29. Murray RJ, et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992;176:157-168.
30. 30. Levitskaya J, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-I. Nature 1995;375:685-688.
31. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997;7:791-802.
32. 32. Khanna R, Burrows SR, Steigerwald-Mullen PM, Moss DJ, Kurilla MG, Cooper L. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int Immunol 1997;9:1537-1543.
33. 33. Bogedain C, Wolf H, Modrow S, Stuber G, Jilg W. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol 1995;69:4872-4879.
34. 34. Pepperl S, Benninger-Doring G, Modrow S, Wolf H, Jilg W. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. J Virol 1998;72:8644-8649.
35. + T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-1835.
36. 36. Khanna R, Sherritt M, Burrows SR. EBV Structural antigens, gp350 and gp85, as targets for ex vivo Virus-Specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol 1999;162:3063-3069.
37. 37. Elliott SL, Pye SJ, Schmidt C, Cross SM, Silins SL, Misko IS. Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection. J Infect Dis 1997;176:1068-1072.
38. 38. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 1997;185:1605-1617.
39. 39. Tomkinson BE, Maziarz R, Sullivan JL. Characterization of the T-cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol 1989;143:660-670.
40. 40. Moss DJ, Rickinson AB, Wallace LE, Epstein MA. Sequential appearance of Epstein-Barr virus nuclear and lymphocyte-detected membrane antigens in B cell transformation. Nature 1981;291:664-666.
41. 41. Strang G, Rickinson AB. Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis. Eur J Immunol 1987;17:1007-1013.
42. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-1402.
43. + virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. Virology 1996;219:489-492.
44. 44. Schmidt CW, Misko IS. The ecology and pathology of Epstein-Barr virus. Immunol Cell Biol 1995;73:489-504.
45. 45. Misko IS, Soszynski TD, Kane RG, Pope JH. Factors influencing the human cytotoxic T-cell response to autologous lymphoblastoid cell lines in vitro. Clin Immunol Immunopathol 1984;32:285-297.
46. 46. Misko IS, Kane RG, Pope JH. Generation in vitro of EBV-induced specific cytotoxic T-cells in autologous serum avoids complications due to self-preferred foetal calf serum-specific T-cell cytotoxicity. Int J Cancer 1981;27:513-519.
47. 47. Burrows SR, et al. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol 1994;75:2489-2493.
48. 48. Khanna R, Burrows SR, Neisig A, Neefjes J, Moss DJ, Silins SL. Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines [published erratum appears in J Virol 1997; 71:9859]. J Virol 1997;71:7429-7435.
49. 49. Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, Watkins PE. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. J Gen Virol 1992;73:449-453.
50. 50. Young LS, Finerty S, Brooks L, Scullion F, Rickinson AB, Morgan AJ. Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins. J Virol 1989;63:1967-1974.
51. 51. Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985;318:287-289.
52. 52. Wilson AD, Lovgren-Bengytsson K, Villacres-Erricsson M, Morein B, Morgan AD. The major Epstein-barr virus (EBV) envelope glycoprotein gp340 when incorporated into ISCOMS primes cytotoxic T cell responses against EBV. Vaccine 1999;17:1282-1290.
53. 53. Wedderburn N, Edwards JM, Desgranges C, Fontaine C, Cohen B, de-Thé G. Infectious mononucleosis-like response in common marmosets infected with Epstein-Barr virus. J Infect Dis 1984;150:878-882.
54. 54. Shope T, Dechairo D, Miller G. Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus. Proc Natl Acad Sci USA 1973;70:2487-2491.
55. 55. Epstein MA, Rabin H, Ball G, Rickinson AB, Jarvis J, Melendez LV. Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus). II. EB virus in a cell line from an animal with reticuloproliferative disease. Int J Cancer 1973;12:319-332.
56. 56. Gerber P, Kalter SS, Schidlovsky G, Peterson WD, Jr., Daniel MD. Biologic and antigenic characteristics of Epstein-Barr virus-related herpesviruses of chimpanzees and baboons. Int J Cancer 1977;20:448-459.
57. 57. Franken M, Annis B, Ali AN, Wang F. 5′ Coding and regulatory region sequence divergente with conserved function of the Epstein-Barr virus LMF2A homolog in herpesvirus papio. J Virol 1995;69:8011-8019.
58. 58. Feichtinger H, et al. A monkey model for Epstein Barr virus-associated lymphomagenesis in human acquired immunodeficiency syndrome. J Exp Med 1992;176:281-286.
59. 59. Frank A, Andiman WA, Miller G. Epstein-Barr virus and nonhuman primates: natural and experimental infection. Adv Cancer Res 1976;23:171-201.
60. 60. Gerber P, Branch JW, Rosenblum EN. Attempts to transmit infectious mononucleosis to rhesus monkeys and marmosets and to isolate herpes-like virus. Proc Soc Exp Biol Med 1969;130:14-19.
61. 61. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science 1997;276:2030-2033.
62. 62. Bertoni R, et al. Human class I supertypes and CTL repertoires extend to chimpanzees. J Immunol 1998;161:4447-4455.
63. 63. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988;335:256-259.
64. 64. Veronese ML, et al. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation. J Exp Med 1992;176:1763-1767.
65. 65. Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, Lyerly HK. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 1993;114:218-225.
66. 66. Rooney CM, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
67. 67. Ishioka GY, et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccine encoding multiple HLA-restricted CTL epitopes. J Immunol 1999;162:3915-3925.
68. 68. Efstathiou S, Ho YM, Hall S, Styles CJ, Scott SD, Gompels UA. Murine herpesvirus 68 is genetically related to the gammaherpesviruses, Epstein-Barr virus and herpesvirus saimiri. J Gen Virol 1990;71:1365-1372.
69. 69. Sunil-Chandra NP, Efstathiou S, Arno J, Nash AA. Virological and pathological features of mice infected with murine gamma herpesvirus 68. J Gen Virol 1992;73:2347-2356.
70. 70. Svobodova J, et al. Antigenic relatedness of alphaherpesviruses isolated from free-living rodents. Acta Virol 1982;26:438-443.
71. 71. Nash AA, Sunil-Chandra NP. Interactions of the murine gammaherpesvirus with the immune system. Curr Opin Immunol 1994;6:560-563.
72. 72. Ehtisham S, Sunil-Chandra NP, Nash AA. Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T-cells. J Virol 1993;67:5247-5252.
73. 73. Sunil-Chandra NP, Efstathiou S, Nash AA. Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. J Gen Virol 1992;73:3275-3279.
74. 74. Stewart JP, Behm FG, Arrand JR, Rooney CM. Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology 1994;200:724-732.
75. 75. Morgan AJ. Epstein-Barr virus vaccines. Vaccine 1992;10:563-571.
76. 76. Finerty S, Mackett M, Arrand JR, Watkins PE, Tarlton J, Morgan AJ. Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum. Vaccine 1994;12:1180-1184.
77. 77. Wilson AD, Shooshstari M, Finerty S, Watkins P, Morgan AJ. Virus-specific cytotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV). Clin Exp Immunol 1996;103:199-205.
78. 78. Gu SY, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995;84:171-177.
79. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
80. 80. Sidney J, Grey HM, Kubo RT, Selle A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 1996;17:261-266.
81. 81. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1);evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998;28:451-458.
82. + cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci USA 1995;92:5845-5849.
83. 83. Thomson SA, et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol 1996;157:822-826.
84. 84. Nardelli-Haefliger D, et al. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 1996;64:5219-5224.
85. 85. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-648.
86. 86. Dambaugh T, Hennessy K, Chamnankit L, Kieff E. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci USA 1984;81:7632-7636.
87. 87. Burrows JM, Burrows SR, Poulsen LM, Sculley TB, Moss DJ, Khanna R. Unusually high freqency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol 1996;70:2490-2496.
88. 88. Khanna R, et al. Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol 1997;71:8340-8346.
89. 89. Khanna R, Burrows SR, Burrows JM. The role of cytotoxic T lymphocytes in the evolution of genetically stable viruses. Trends Microbiol 1997;5:64-69.
90. 90. Kyaw MT, et al. Expression of B-type Epstein-Barr virus in HIV-infected patients and cardiac transplant recipients. AIDS Res Hum Retroviruses 1992;8:1869-1874.
91. 91. Khanna R. Tumour surveillance: missing peptides and MHC molecules. Immunol Cell Biol 1998;76:20-26.
92. 92. Rooney CM, Rowe M, Wallace LE, Rickinson AB. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 1985;317:629-631.
93. 93. Moss DJ, Burrows SR, Castelino DJ, Kane RG, Pope JH, Rickinson AB. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int J Cancer 1983;31:727-732.
94. 94. Andersson ML, Stam NJ, Klein G, Ploegh HL, Masucci MG. Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells. Int J Cancer 1991;47:544-550.
95. 95. Khanna R, Burrows SR, Argaet V, Moss DJ. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol 1994;6:639-645.
96. 96. Khanna R, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-dass I antigen expression. Eur J Immunol 1995;25:1374-1384.
97. 97. Restifo NP, et al. Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol 1995;154:4414-4422.
98. 98. Rowe DT, Rowe M, Evan GI, Wallace LE, Farrell PJ, Rickinson AB. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J 1986;5:2599-2607.
99. 99. Torsteinsdottir S, Masucci MG, Brautbar C, Lenoir G, Klein G, Klein E. Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones. Cell Immunol 1986;98:453-466.
100. 100. Wang JH, et al. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature 1990;348:411-418.
101. 101. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor k B. J Biol Chem 1992;267:24157-24160.
102. 102. Hammarskjöld ML, Simurda MC. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κ B activity. J Virol 1992;66:6496-6501.
103. 103. Loh JE, Chang CH, Fodor WL, Flavell RA. Dissection of the interferon γ-MHC class II signal transduction pathway reveals that type I and type II interferon systems share common signalling component (s). EMBO J 1992;11:1351-1363.
104. 104. Khanna R, Cooper L, Kienzle N, Moss DJ, Burrows SR, Khanna KK. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 1997;159:5782-5785.
105. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer 1994;58:69-79.
106. 106. Khanna R, Busson P, Burrows SR, et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res 1998;58:310-314.
107. 107. Lee SP, et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T cell recognition. Blood 1998;92:1020-1030.
108. 108. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 1995;182:477-486.
109. 109. Khanna R, Burrows SR, Moss DJ, Silins SL. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein ZA: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol 1996;70:5357-5362.
110. 110. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV specific cytotoxic T cells. Ann Oncol 1998;9:S129-32.
111. 111. Roskrow MA, et al. Administration of neomycin resistance gene marked, EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther 1998;9:1237-1250.
112. 112. Roskrow MA, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998;91:2925-2934.